Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice
Age ≥ 18 years
Diagnosis of radically resected IB-IIIA NSCLC with EGFR activating mutation
Treatment with adjuvant osimertinib (starting from September 2022, date of approval) according to clinical practice
Recurrence of disease during or after adjuvant therapy with osimertinib received according to clinical practice
Unavailability of tissue and/or liquid biopsy sample collected at the time of recurrence
Concomitant synchronous malignancies aside from NSCLC or any concurrent and/or active malignancy that has required treatment within 2 years
Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site).